Preparation of TH227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability.
In this study, the feasibility of constructing radioimmunoconjugates by using the novel therapeutic candidate alpha-emitter, (227)Th, was evaluated. By use of the bifunctional chelator, p-SCN-benzyl-DOTA, (227)Th was conjugated to the two monoclonal antibodies, rituximab and trastuzumab. Their stability in 80% fetal bovine serum at 37 degrees C was measured. The immunoreactive fractions were determined by using CD20- and HER/2-positive cells, respectively. The overall labeling yield spanned from 6% to 17%. The radioimmunoconjugates demonstrated a relevant stability in serum and showed appropriate antigen-binding abilities.
Larsen
Roy H
RH
Department of Radiation Biology, University of Oslo and The Norwegian Radium Hospital, Oslo, Norway.
Borrebaek
Jorgen
J
Dahle
Jostein
J
Melhus
Katrine B
KB
Krogh
Cecilie
C
Valan
Miriam H
MH
Bruland
Oyvind S
OS
D000911:Antibodies, Monoclonal / Q000097:blood; D000941:Antigens; D045744:Cell Line, Tumor; D004355:Drug Stability; D006573:Heterocyclic Compounds, 1-Ring; D006801:Humans; D018796:Immunoconjugates / Q000097:blood*; D007202:Indicators and Reagents; D013910:Thorium / Q000097:blood / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000941:Antigens; D006573:Heterocyclic Compounds, 1-Ring; D018796:Immunoconjugates; D007202:Indicators and Reagents; C071349:1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid; D013910:Thorium